File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Treat-and-extend regimen for management of neovascular agerelated macular degeneration: recommendations from the Hong Kong Retina Expert Panel

TitleTreat-and-extend regimen for management of neovascular agerelated macular degeneration: recommendations from the Hong Kong Retina Expert Panel
Authors
KeywordsAflibercept
Macular degeneration
Ranibizumab
Vascular endothelial growth factors
Issue Date2019
PublisherCollege of Ophthalmologists of Hong Kong. The Journal's web site is located at https://hkjo.hk/index.php/hkjo/index
Citation
Hong Kong Journal of Ophthalmology, 2019, v. 23 n. 1, p. 15-19 How to Cite?
AbstractAntivascular endothelial growth factor (anti-VEGF) agents are a safe and effective treatment option for neovascular age-related macular degeneration (nAMD). However, undertreatment related to the costs and route of administration of anti-VEGF agents remains a common problem for nAMD patients. The treat-and-extend (T&E) regimen for nAMD has proven to balance clinical effectivity with reduced numbers of injections. However, implementation of the T&E regimen depends on the capacity and resources of clinics and patient compliance. To determine the optimal T&E regimen for Hong Kong, a panel of retina specialists was initiated by MediPaper Medical Communications Limited to discuss the benefits and hurdles in adopting the T&E regimen and to develop recommendations for patient selection based on clinical needs, dosing criteria, and dosing regimen. Key recommendations included selecting patients with only-eye or recurrence for the T&E regimen, pre-booking clinic appointments to reduce patient visits, communicating the T&E regimen with non-vitreoretinal physicians and trainees, extending the maximum dose interval to 16 weeks, and actively engaging patients in decision making.
Persistent Identifierhttp://hdl.handle.net/10722/286090
ISSN

 

DC FieldValueLanguage
dc.contributor.authorWong, IYH-
dc.contributor.authorNg, DSC-
dc.contributor.authorFung, NSK-
dc.contributor.authorChan, Y-
dc.contributor.authorChung, DCY-
dc.contributor.authorHo, M-
dc.contributor.authorKo, CKL-
dc.contributor.authorLeung, JWY-
dc.contributor.authorMohammed, S-
dc.contributor.authorWong, RLM-
dc.contributor.authorLai, TYY-
dc.contributor.authorSin, HPY-
dc.contributor.authorTang, HHY-
dc.date.accessioned2020-08-31T06:58:57Z-
dc.date.available2020-08-31T06:58:57Z-
dc.date.issued2019-
dc.identifier.citationHong Kong Journal of Ophthalmology, 2019, v. 23 n. 1, p. 15-19-
dc.identifier.issn1027-8230-
dc.identifier.urihttp://hdl.handle.net/10722/286090-
dc.description.abstractAntivascular endothelial growth factor (anti-VEGF) agents are a safe and effective treatment option for neovascular age-related macular degeneration (nAMD). However, undertreatment related to the costs and route of administration of anti-VEGF agents remains a common problem for nAMD patients. The treat-and-extend (T&E) regimen for nAMD has proven to balance clinical effectivity with reduced numbers of injections. However, implementation of the T&E regimen depends on the capacity and resources of clinics and patient compliance. To determine the optimal T&E regimen for Hong Kong, a panel of retina specialists was initiated by MediPaper Medical Communications Limited to discuss the benefits and hurdles in adopting the T&E regimen and to develop recommendations for patient selection based on clinical needs, dosing criteria, and dosing regimen. Key recommendations included selecting patients with only-eye or recurrence for the T&E regimen, pre-booking clinic appointments to reduce patient visits, communicating the T&E regimen with non-vitreoretinal physicians and trainees, extending the maximum dose interval to 16 weeks, and actively engaging patients in decision making.-
dc.languageeng-
dc.publisherCollege of Ophthalmologists of Hong Kong. The Journal's web site is located at https://hkjo.hk/index.php/hkjo/index-
dc.relation.ispartofHong Kong Journal of Ophthalmology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAflibercept-
dc.subjectMacular degeneration-
dc.subjectRanibizumab-
dc.subjectVascular endothelial growth factors-
dc.titleTreat-and-extend regimen for management of neovascular agerelated macular degeneration: recommendations from the Hong Kong Retina Expert Panel-
dc.typeArticle-
dc.identifier.emailWong, IYH: wongyhi@hku.hk-
dc.identifier.emailFung, NSK: nfung@hku.hk-
dc.identifier.authorityWong, IYH=rp01467-
dc.identifier.authorityFung, NSK=rp02505-
dc.description.naturepublished_or_final_version-
dc.identifier.hkuros313063-
dc.identifier.volume23-
dc.identifier.issue1-
dc.identifier.spage15-
dc.identifier.epage19-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats